AUS
NZ
UK
CA
USA
IND
Highlights
- Pro Medicus (ASX:PME) reports a 42.7% increase in net profit for the first half of FY24.
- Record-breaking contract wins, including the largest deal in company history worth $330 million.
- Company remains debt-free with solid cash reserves of $182.3 million.
Pro Medicus (ASX:PME), a leader in health imaging technology, has posted impressive financial results for the six months ending December 2024, showing a significant 42.7% increase in net profit. The company recorded a net profit of $51.7 million, up from the previous corresponding period, driven by strong growth across its key markets.
The company’s revenue from ordinary activities reached $97.2 million, reflecting a 31.1% increase compared to the same period last year. This growth was mainly fueled by Pro Medicus's expansion in North America, where regional revenue surged by 34.6%, reaching $86.4 million. This uptick underscores the company's growing presence in the healthcare sector, particularly in the U.S. market.
Pro Medicus’s solid financial performance is further highlighted by its strong balance sheet. As of December 2024, the company reported a 17.7% increase in cash and other financial assets, totaling $182.3 million, while maintaining a debt-free position. This robust cash flow positions Pro Medicus for future expansion and innovation in the highly competitive health imaging industry.
A key driver of the company’s growth has been its successful acquisition of high-value contracts. Notably, Pro Medicus secured contracts with several major healthcare providers, including Trinity Health, Lurie Children’s Hospital, and Duly Health and Care. The largest of these deals, with Trinity Health, is valued at $330 million and marks the company’s biggest win in its history. These contracts span up to 10 years, providing Pro Medicus with stable long-term revenue streams.
Additionally, the company renewed its agreement with US-based Mercy Health, valued at $98 million over eight years, and secured another $32 million contract with a prominent Australian radiology practice. Pro Medicus also expanded its existing relationships, adding new modules to contracts with Duke Health ($15 million over five years) and NYU Langone ($24 million over five years).
CEO Dr. Sam Hupert expressed confidence in the company’s future, stating that the period marked a record in both financial performance and contract wins. He emphasized the company’s commitment to improving its implementation processes, ensuring that clients are quickly able to realize the full value of their contracts. Pro Medicus’s strong pipeline of contracts across various client segments indicates continued growth and market dominance.
With these positive developments, Pro Medicus remains well-positioned to capitalize on future opportunities in the healthcare sector, solidifying its leadership in health imaging solutions.
